European Society for Medical Oncology Immuno-Oncology Congress 2023

Description

+ Include: 123 videos + 260 pdfs, size: 15.1 GB

+ Target Audience: oncologist, immunologist

+ Sample video: contact me for sample video

+ Information:

+ Topics:

Anti-cancer pathogen-derived therapies Dressing up viruses to fool cancer Personalised oncolytic vaccine for solid tumours.mp4
Anti-cancer pathogen-derived therapies Dressing up viruses to fool cancer Personalised oncolytic vaccine for solid tumours.pdf
Anti-cancer pathogen-derived therapies Mechanisms employed by the tumour microbiome to mediate responses to immunotherapy.mp4
Anti-cancer pathogen-derived therapies Mechanisms employed by the tumour microbiome to mediate responses to immunotherapy.pdf
Anti-cancer pathogen-derived therapies Q&A and discussion.mp4
Breast cancer Biomarkers for immunotherapy in breast cancer.mp4
Breast cancer Biomarkers for immunotherapy in breast cancer.pdf
Breast cancer Clinical overview of immunotherapy in breast cancer.mp4
Breast cancer Clinical overview of immunotherapy in breast cancer.pdf
Breast cancer Development of non-T cell immunotherapy in breast cancer.mp4
Breast cancer Development of non-T cell immunotherapy in breast cancer.pdf
Breast cancer Immune biology in breast cancer.mp4
Breast cancer Immune biology in breast cancer.pdf
Breast cancer Q&A and discussion.mp4
Cancer vaccines Cancer vaccination in hepatocellular carcinoma (HCC).mp4
Cancer vaccines Cancer vaccination in hepatocellular carcinoma (HCC).pdf
Cancer vaccines Cell-based vaccination.mp4
Cancer vaccines Cell-based vaccination.pdf
Cancer vaccines Q&A and discussion.mp4
Cell therapies CAR T-cells for haematological malignancies The Barcelona experience.mp4
Cell therapies CAR T-cells for haematological malignancies The Barcelona experience.pdf
Cell therapies Q&A and discussion.mp4
Cell therapies TIL therapy in melanoma.mp4
Cell therapies TIL therapy in melanoma.pdf
Cell therapy vs bispecific antibodies Bispecific antibodies.mp4
Cell therapy vs bispecific antibodies Bispecific antibodies.pdf
Cell therapy vs bispecific antibodies Introduction and first vote.mp4
Cell therapy vs bispecific antibodies Introduction and first vote.pdf
Cell therapy vs bispecific antibodies Second vote and conclusions.mp4
Cell therapy vs bispecific antibodies Second vote and conclusions.pdf
Co-formulation bispecific approaches Anti-CD30 bispecific (Fc engager) programme.mp4
Co-formulation bispecific approaches Anti-CD30 bispecific (Fc engager) programme.pdf
Co-formulation bispecific approaches Anti-DLL3 x CD3 BiTe.mp4
Co-formulation bispecific approaches Anti-DLL3 x CD3 BiTe.pdf
Co-formulation bispecific approaches Insights from tebentafusp, the first TCR therapeutic.mp4
Co-formulation bispecific approaches Insights from tebentafusp, the first TCR therapeutic.pdf
Co-formulation bispecific approaches Q&A and discussion.mp4
Co-formulation bispecific approaches Teclistamab as a challenge to CAR T.mp4
Co-formulation bispecific approaches Teclistamab as a challenge to CAR T.pdf
Collaborative session ESMO-SITC Deep immunophenotyping to identify biomarkers and therapeutic targets in solid tumors.mp4
Collaborative session ESMO-SITC Deep immunophenotyping to identify biomarkers and therapeutic targets in solid tumors.pdf
Collaborative session ESMO-SITC Lessons learned from combination immunotherapy in GU cancers.mp4
Collaborative session ESMO-SITC Lessons learned from combination immunotherapy in GU cancers.pdf
Collaborative session ESMO-SITC Lessons learned from combination immunotherapy in melanoma.mp4
Collaborative session ESMO-SITC Lessons learned from combination immunotherapy in melanoma.pdf
Collaborative session ESMO-SITC Panel discussion Biological stratification of patients for better immunotherapy.mp4
Collaborative session ESMO-SITC Q&A 1.mp4
Collaborative session ESMO-SITC Q&A 2.mp4
Collaborative session ESMO-SITC Q&A 3.mp4
Collaborative session ESMO-SITC Welcome and introduction.mp4
Epigenetic remodelling cfDNA epigenetics.mp4
Epigenetic remodelling Q&A and discussion.mp4
Epigenetic remodelling T cell epigenetics.mp4
Epigenetic remodelling T cell epigenetics.pdf
ESMO Colloquium supported by Novocure Clinical evidence for efficacy &safety of electric fields as monotherapy.mp4
ESMO Colloquium supported by Novocure Clinical evidence for efficacy &safety of electric fields as monotherapy.pdf
ESMO Colloquium supported by Novocure Concluding remarks.mp4
ESMO Colloquium supported by Novocure Q&A and discussion.mp4
ESMO Colloquium supported by Novocure Research insights in future developments of electric field applications in oncology.mp4
ESMO Colloquium supported by Novocure Research insights in future developments of electric field applications in oncology.pdf
ESMO Colloquium supported by Novocure Welcome and introduction.mp4
final_programme_immuno23hybrid.pdf
Gastrointestinal tumours Cellular therapy for GI cancer.mp4
Gastrointestinal tumours Cellular therapy for GI cancer.pdf
Gastrointestinal tumours Immunotherapy for metastatic colorectal cancer.mp4
Gastrointestinal tumours Immunotherapy for metastatic colorectal cancer.pdf
Gastrointestinal tumours Immunotherapy for metastatic upper GI cancer.mp4
Gastrointestinal tumours Immunotherapy for metastatic upper GI cancer.pdf
Gastrointestinal tumours Perioperative immunotherapy for GI cancer.mp4
Gastrointestinal tumours Perioperative immunotherapy for GI cancer.pdf
Gastrointestinal tumours Q&A and discussion.mp4
Genitourinary tumours I-O in all patients for mRCC.mp4
Genitourinary tumours I-O in all patients for mRCC.pdf
Genitourinary tumours Q&A and discussion.mp4
Genitourinary tumours Searching for I-O in prostate cancer.mp4
Genitourinary tumours Searching for I-O in prostate cancer.pdf
Genitourinary tumours Where I-O makes sense in urothelial carcinoma.mp4
Genitourinary tumours Where I-O makes sense in urothelial carcinoma.pdf
Gynaecological malignancies A deep look at checkpoints inhibitors in ovarian cancer treatment Why this couple doesn’t seem to work.mp4
Gynaecological malignancies A deep look at checkpoints inhibitors in ovarian cancer treatment Why this couple doesn’t seem to work.pdf
Gynaecological malignancies Are PD-L1 and MMR status paving the way of personalised medicine in gynaecological tumours.mp4
Gynaecological malignancies Are PD-L1 and MMR status paving the way of personalised medicine in gynaecological tumours.pdf
Gynaecological malignancies Is immunotherapy beating advanced cervical cancer.mp4
Gynaecological malignancies Is immunotherapy beating advanced cervical cancer.pdf
Gynaecological malignancies Q&A and discussion.mp4
Gynaecological malignancies The immunotherapy arrival A paradigm shift in advanced endometrial cancer treatment.mp4
Gynaecological malignancies The immunotherapy arrival A paradigm shift in advanced endometrial cancer treatment.pdf
Haematological malignancies Current state and future prospects of immunotherapy for lymphoid malignancies.mp4
Haematological malignancies Current state and future prospects of immunotherapy for lymphoid malignancies.pdf
Haematological malignancies Current state and future prospects of immunotherapy for multiple myeloma.mp4
Haematological malignancies Current state and future prospects of immunotherapy for multiple myeloma.pdf
Haematological malignancies Q&A and discussion.mp4
Haematological malignancies The immunology of immune cell cancers.mp4
Haematological malignancies The immunology of immune cell cancers.pdf
Head and neck cancer Combination therapy Using novel approaches to identify novel biomarkers, inform patient selection and design trials.mp4
Head and neck cancer Combination therapy Using novel approaches to identify novel biomarkers, inform patient selection and design trials.pdf
Head and neck cancer Preclinical data to inform combinatorial radiation Immunotherapy clinical design in locally advanced disease.mp4
Head and neck cancer Preclinical data to inform combinatorial radiation Immunotherapy clinical design in locally advanced disease.pdf
Head and neck cancer Q&A and discussion.mp4
Head and neck cancer Revisiting neoadjuvant therapy in the immunotherapy era.mp4
Head and neck cancer Revisiting neoadjuvant therapy in the immunotherapy era.pdf
Improved immune monitoring for better drug development in I-O A deep dive into transcriptomics of immune cells thanks to single cell RNAseq.mp4
Improved immune monitoring for better drug development in I-O A deep dive into transcriptomics of immune cells thanks to single cell RNAseq.pdf
Improved immune monitoring for better drug development in I-O Integrated multi omic correlation with clinical response in I-O.mp4
Improved immune monitoring for better drug development in I-O Integrated multi omic correlation with clinical response in I-O.pdf
Improved immune monitoring for better drug development in I-O Q&A and discussion.mp4
Improved immune monitoring for better drug development in I-O Value of fresh material assessment in early phase clinical trials.mp4
Improved immune monitoring for better drug development in I-O Value of fresh material assessment in early phase clinical trials.pdf
Is TMB a good predictive biomarker for immunotherapy Introduction and first vote.mp4
Is TMB a good predictive biomarker for immunotherapy Introduction and first vote.pdf
Is TMB a good predictive biomarker for immunotherapy No.mp4
Is TMB a good predictive biomarker for immunotherapy No.pdf
Is TMB a good predictive biomarker for immunotherapy Second vote and conclusions.mp4
Is TMB a good predictive biomarker for immunotherapy Second vote and conclusions.pdf
Is TMB a good predictive biomarker for immunotherapy Yes.mp4
Is TMB a good predictive biomarker for immunotherapy Yes.pdf
Joint ESMO-SITC Immunotherapy Primer Conclusions.mp4
Joint ESMO-SITC Immunotherapy Primer Myeloid cells as critical players in the TME.mp4
Joint ESMO-SITC Immunotherapy Primer Myeloid cells as critical players in the TME.pdf
Joint ESMO-SITC Immunotherapy Primer Panel discussion.mp4
Joint ESMO-SITC Immunotherapy Primer Principles of tumour immunity.mp4
Joint ESMO-SITC Immunotherapy Primer Principles of tumour immunity.pdf
Joint ESMO-SITC Immunotherapy Primer Q&A 1.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 2.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 3.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 4.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 5.mp4
Joint ESMO-SITC Immunotherapy Primer Q&A 6.mp4
Joint ESMO-SITC Immunotherapy Primer Welcome and introduction.mp4
Leveraging insights from basic cancer immunology for translation Q&A and discussion.mp4
Leveraging insights from basic cancer immunology for translation Role of androgen receptor activity in T cell inhibition and potential for therapeutic intervention.mp4
Leveraging insights from basic cancer immunology for translation Role of androgen receptor activity in T cell inhibition and potential for therapeutic intervention.pdf
Leveraging insights from basic cancer immunology for translation Understanding T cell locations and targetable reservoirs for therapeutic modulation.mp4
Leveraging insights from basic cancer immunology for translation Understanding T cell locations and targetable reservoirs for therapeutic modulation.pdf
Mesothelioma I-O combinations in later line therapy for mesothelioma.mp4
Mesothelioma I-O combinations in later line therapy for mesothelioma.pdf
Mesothelioma Q&A and discussion.mp4
Mini Oral session Adjuvant Pembrolizumab versus Placebo for Early-Stage NSCLC After Resection and Optional Chemotherapy Updated Results From PEARLS KEYNOTE-091.mp4
Mini Oral session Adjuvant Pembrolizumab versus Placebo for Early-Stage NSCLC After Resection and Optional Chemotherapy Updated Results From PEARLS KEYNOTE-091.pdf
Mini Oral session Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma.mp4
Mini Oral session Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma.pdf
Mini Oral session Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes.mp4
Mini Oral session Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes.pdf
Mini Oral session Invited Discussant 163MO.mp4
Mini Oral session Invited Discussant 163MO.pdf
Mini Oral session Invited Discussant 67MO, LBA4 and 120MO.mp4
Mini Oral session Invited Discussant 67MO, LBA4 and 120MO.pdf
Mini Oral session Low-dose stereotactic body radiotherapy prior to pre-operative cemiplimab for patients with resectable hepatocellular carcinoma.mp4
Mini Oral session Low-dose stereotactic body radiotherapy prior to pre-operative cemiplimab for patients with resectable hepatocellular carcinoma.pdf
New targets and tumour microenvironment NK targets for cancer immunotherapy.mp4
New targets and tumour microenvironment NK targets for cancer immunotherapy.pdf
New targets and tumour microenvironment Q&A and discussion.mp4
New targets and tumour microenvironment Tumour inflammation as a target.mp4
New targets and tumour microenvironment Tumour inflammation as a target.pdf
Novel clinical and translational insights in melanoma Adoptive cell transfer Challenges and future directions.mp4
Novel clinical and translational insights in melanoma Adoptive cell transfer Challenges and future directions.pdf
Novel clinical and translational insights in melanoma New target in I-O based combination in melanoma.mp4
Novel clinical and translational insights in melanoma New target in I-O based combination in melanoma.pdf
Novel clinical and translational insights in melanoma Peptidomics.mp4
Novel clinical and translational insights in melanoma Peptidomics.pdf
Novel clinical and translational insights in melanoma Q&A and discussion.mp4
Opening session and 2023 Award Introduction to the 2023 Award keynote lecture.mp4
Opening session and 2023 Award Introduction to the 2023 Award keynote lecture.pdf
Opening session and 2023 Award Lymphocytes as a living drug for the treatment of cancer.mp4
Opening session and 2023 Award Lymphocytes as a living drug for the treatment of cancer.pdf
Opening session and 2023 Award Welcome to the ESMO Immuno-Oncology Congress 2023.mp4
Opening session and 2023 Award Welcome to the ESMO Immuno-Oncology Congress 2023.pdf
Poster Display 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms.pdf
Poster Display A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management.pdf
Poster Display A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses.pdf
Poster Display A novel multi-organ on chip model for metastatic tumor biology understanding.pdf
Poster Display A Phase 1 2, Open-label Study of an Anti-ILT2 (LILRB1) Antibody, SAR444881, Administered Alone and in Combination With Pembrolizumab.pdf
Poster Display A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors.pdf
Poster Display A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors.pdf
Poster Display A phase I clinical trial of QLS31905 in advanced solid tumors.pdf
Poster Display A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody tislelizumab.pdf
Poster Display A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen- MIZAR trial.pdf
Poster Display A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1 PD-L1 resistant melanoma or NSCLC patients- the run-in phase of the NIBIT Foundation ML1 Study.pdf
Poster Display A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC.pdf
Poster Display A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer.pdf
Poster Display A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma.pdf
Poster Display A single-arm, multicenter phase – trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).pdf
Poster Display A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC).pdf
Poster Display A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer.pdf
Poster Display Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures- from Imaging Mass Cytometry Data to Pathology Applications.pdf
Poster Display Adaptive NK cells as a therapeutic option for childhood leukaemia.pdf
Poster Display Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC)- 3-year update of the phase 3 CAPSTONE-1 study.pdf
Poster Display Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594.pdf
Poster Display Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB).pdf
Poster Display An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles.pdf
Poster Display An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4.pdf
Poster Display Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases.pdf
Poster Display Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL).pdf
Poster Display Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy.pdf
Poster Display Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in patients with advanced NSCLC- a cohort study adjusting for immortal-time bias.pdf
Poster Display Bladder-Sparing Treatment for muscle-invasive bladder carcinoma (MIBC)- A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab.pdf
Poster Display Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC.pdf
Poster Display Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)- an open-label, multicenter phase – trial (AK104-IIT-014).pdf
Poster Display Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer-A multi-center, single-arm, phase 2 study.pdf
Poster Display Camrelizumab plus famitinib as first-line treatment in patient with locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE)-A multi-center, single-arm, phase II study.pdf
Poster Display Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory NSCLC.pdf
Poster Display CD161+CD127+CD8+ T cells as a critical predictor of the efficacy of anti-PD-1 immunotherapy in diabetic patients with non-small cell lung cancer.pdf
Poster Display CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma.pdf
Poster Display Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours.pdf
Poster Display Characterization of pre-exhausted exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB)..pdf
Poster Display Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer.pdf
Poster Display Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC) a hypothesis-generating analysis.pdf
Poster Display Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment.pdf
Poster Display Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma.pdf
Poster Display Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors.pdf
Poster Display Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score.pdf
Poster Display Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer.pdf
Poster Display Contrasting drivers of response to immunotherapy across solid tumour types- results from analysis of 2500 cases.pdf
Poster Display Deciphering tumor microenvironment heterogeneity between primary tumor and metastases in high grade serous ovarian cancer (HGSC) to predict response to immunotherapy (IT).pdf
Poster Display Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.pdf
Poster Display Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer.pdf
Poster Display Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer.pdf
Poster Display Discovery of best-in-class dual-acting A2AR A2BR antagonists that are functional in high adenosine environment.pdf
Poster Display Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer.pdf
Poster Display Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data.pdf
Poster Display Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1 NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma.pdf
Poster Display DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex.pdf
Poster Display Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT)- updated efficacy and safety analysis.pdf
Poster Display Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy immunotherapy..pdf
Poster Display Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC.pdf
Poster Display Effect of STAT6 Inhibition as a Novel Strategy for Promoting the Induction of Potent and Stable Regulatory T Cells for Use in Colitis Therapy.pdf
Poster Display Efficacy and biomarker exploration of Anlotinib plus Penpulimab for extensive stage Small cell lung cancer who failed from previous Platinum-Based Chemotherapy Result from A phase II.pdf
Poster Display Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01).pdf
Poster Display Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer.pdf
Poster Display Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts).pdf
Poster Display Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform.pdf
Poster Display Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2.pdf
Poster Display Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer.pdf
Poster Display Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma.pdf
Poster Display Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors- SAFFRON-103.pdf
Poster Display Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study.pdf
Poster Display Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer.pdf
Poster Display Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes.pdf
Poster Display Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment.pdf
Poster Display Final Analysis of the French Real-World Study EVIDENS- Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC).pdf
Poster Display First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors.pdf
Poster Display First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma.pdf
Poster Display FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells.pdf
Poster Display Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1 GM-CSF.pdf
Poster Display HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC)- a phase II trial.pdf
Poster Display Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma.pdf
Poster Display Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients – assessment of lesion-level response with 18F-FDG PET CT.pdf
Poster Display HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo.pdf
Poster Display High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer.pdf
Poster Display HLA SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses.pdf
Poster Display ICI for patients with MSS metastatic colorectal cancer.pdf
Poster Display Identification of High Confidence Candidate Markers for Macrophage Infiltrating Tumor Microenvironment through Single Cell Genomic Atlases.pdf
Poster Display Identifying novel immunotherapy targets using machine learning and ex vivo validation.pdf
Poster Display Immune and tumor cells expression of VISTA in a panel of cancer indications- A strategy to inform selection of patients treated with anti-VISTA.pdf
Poster Display Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB IV Non-Small Cell Lung Cancer relevance of immunosuppressive factors.pdf
Poster Display Immune landscape and CLEVER-1 expression in hepatoblastoma.pdf
Poster Display Immune-related roles of B7H3 in glioblastoma.pdf
Poster Display Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade.pdf
Poster Display Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors.pdf
Poster Display Immunosuppressive F13A1+ Mo M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers.pdf
Poster Display Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma.pdf
Poster Display Integrated Data Analysis within IMMUcan Identifies Prognostic Features of Early NSCLC.pdf
Poster Display Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response.pdf
Poster Display Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort.pdf
Poster Display Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer.pdf
Poster Display Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.pdf
Poster Display Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours Exploratory Effect Data, Tolerability.pdf
Poster Display Krascendo-170 Lung- a phase Ib II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C advanced non-small cell lung cancer (NSCLC).pdf
Poster Display Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC).pdf
Poster Display LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France- first effectiveness, safety, and IO-rechallenge results.pdf
Poster Display Local and systemic anti-tumor response during tumor development in an immune privileged site- the case of uveal melanoma.pdf
Poster Display Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation.pdf
Poster Display Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab.pdf
Poster Display Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.pdf
Poster Display Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM.pdf
Poster Display Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab tremelimumab vinorelbine efficacy in advanced cervical cancer (iMOVIE)..pdf
Poster Display MDT-BRIDGE- A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients.pdf
Poster Display MicroRNA-548c- An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer.pdf
Poster Display Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1 EMT Modulation.pdf
Poster Display Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study.pdf
Poster Display Natural high-avidity T-cell receptor efficiently mediates regression of cancer testis antigen 83 positive common solid cancers.pdf
Poster Display Naxitamab efficacy in patients with refractory relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score.pdf
Poster Display Outcomes of CUPem- A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary.pdf
Poster Display Patient selection based on hyperprogressive disease risk nearly doubles survival benefit of immune checkpoint blockade- validation of a pan-tumor tissue agnostic combined biomarker approach.pdf
Poster Display Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC)- EMPOWER-lung 3 liver metastases subpopulation.pdf
Poster Display PBGB-HNSCC-201 (NCT05909904)- Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts).pdf
Poster Display Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA) preliminary analysis.pdf
Poster Display Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients.pdf
Poster Display Phase 12 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors.pdf
Poster Display Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M)- preliminary results.pdf
Poster Display Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer- updated efficacy and safety results.pdf
Poster Display Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC).pdf
Poster Display PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment.pdf
Poster Display Polarization of tumor-associated macrophages enhanced by 2-HPcyclodextrin modified PLGA nanoparticles.pdf
Poster Display PosImmune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line.pdf
Poster Display Post-anti-PD1 tumor characterization of HPV-negative R M SCCHN- an EORTC IMMUcan sub-project.pdf
Poster Display Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020.pdf
Poster Display Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced recurrent endometrial cancer treated with Dostarlimab..pdf
Poster Display Preliminary efficacy and safety results from `ReBirth’, a phase II study of risk-based bladder-sparing therapy for MIBC.pdf
Poster Display Primary NSCLC patient-derived microtumors (PMTs) for clinical-relvant prediction of immunotherapy efficacy.pdf
Poster Display Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy.pdf
Poster Display Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study.pdf
Poster Display Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma.pdf
Poster Display Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer.pdf
Poster Display Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg- PRESERV MEL.pdf
Poster Display Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx)- CORRELATE.pdf
Poster Display Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated.pdf
Poster Display Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment- Initial Findings of a Belgian Multicenter Study.pdf
Poster Display REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer- Phase 1 dose-escalation study.pdf
Poster Display Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform.pdf
Poster Display Role of aerobic exercise training on the mitochondrial metabolism and effector function of CD8+ tumor-infiltrating lymphocytes.pdf
Poster Display Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors- Phase 2b Dose-Expansion Trial in Progress.pdf
Poster Display Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors- Results of phase 1 study.pdf
Poster Display Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_).pdf
Poster Display Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium.pdf
Poster Display Senolytic treatment remodels glioblastoma microenvironment.pdf
Poster Display Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis.pdf
Poster Display Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC).pdf
Poster Display Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase b trial.pdf
Poster Display TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma- A propensity score matching study.pdf
Poster Display Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma- a window-of-opportunity trial of nivolumab with BMS-813160 (CCR25i) or BMS-986253 (anti-IL8).pdf
Poster Display Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity.pdf
Poster Display TCCIA- A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy.pdf
Poster Display Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.pdf
Poster Display The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK..pdf
Poster Display The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2 STAT3 BIRC5 signaling.pdf
Poster Display The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma.pdf
Poster Display The Impact of Body Mass Index on Survival Endpoints among Patients with Metastatic Urothelial Carcinoma Undergoing Treatment with Immune Checkpoint Inhibitors A Real-World Multicenter Analysis.pdf
Poster Display The impact of immune microenvironment subopopulations on soft tissue sarcomas.pdf
Poster Display The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1 PD-L1 treatment UV1 vaccination as first line treatment.pdf
Poster Display The prognostic value of soluble CD73 in advanced triple-negative breast cancer an exploratory analysis of the SYNERGY trial.pdf
Poster Display The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy- A Focus on First Dose Timing.pdf
Poster Display The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1.pdf
Poster Display The survival impact of the addition of durvalumab to cisplatin gemcitabine in advanced biliary tract cancer- a real-world, retrospective, multicentric study.pdf
Poster Display Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model.pdf
Poster Display Toward a better understanding of the tumor microenvironment to inform precision oncology approaches..pdf
Poster Display Treatment Sequencing in PD-L1-Positive Recurrent Metastatic (R M) Head and Neck Squamous Cell Carcinoma (HNSCC)- Exploratory Analysis of the Phase 3 KEYNOTE-048 Study.pdf
Poster Display Tumor organoid-derived TIL therapy for colorectal cancer.pdf
Poster Display Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.pdf
Poster Display Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]).pdf
Poster Display Unlocking the Power of Natural Killer Cells- Precision Selection with Cutting-Edge Microfluidics.pdf
PosterChange in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma Evaluation of a Novel Approach.pdf
Proffered Paper session 1 Durvalumab (D) ñ tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC.mp4
Proffered Paper session 1 Durvalumab (D) ñ tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC.pdf
Proffered Paper session 1 First-line (1L) durvalumab plus platinum-etoposide for patients with extensive-stage SCLC (ES-SCLC).mp4
Proffered Paper session 1 First-line (1L) durvalumab plus platinum-etoposide for patients with extensive-stage SCLC (ES-SCLC).pdf
Proffered Paper session 1 Invited Discussant 118O, LBA2 and LBA 3.mp4
Proffered Paper session 1 Invited Discussant 118O, LBA2 and LBA 3.pdf
Proffered Paper session 1 Invited Discussant 64O and 65O.mp4
Proffered Paper session 1 Invited Discussant 64O and 65O.pdf
Proffered Paper session 1 Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy.mp4
Proffered Paper session 1 Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy.pdf
Proffered Paper session 1 Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC).mp4
Proffered Paper session 1 Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC).pdf
Proffered Paper session 1 Q&A.mp4
Proffered Paper session 2 Clinical Experience of Tabelecleucel in Epstein-Barr Virus-Positive Post-transplant Lymphoproliferative Disease (EBV+ PTLD).mp4
Proffered Paper session 2 Clinical Experience of Tabelecleucel in Epstein-Barr Virus-Positive Post-transplant Lymphoproliferative Disease (EBV+ PTLD).pdf
Proffered Paper session 2 Invited Discussant 119O.mp4
Proffered Paper session 2 Invited Discussant 119O.pdf
Proffered Paper session 2 Invited Discussant 48O and 49O.mp4
Proffered Paper session 2 Invited Discussant 48O and 49O.pdf
Proffered Paper session 2 Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy.mp4
Proffered Paper session 2 Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy.pdf
Proffered Paper session 2 Q&A 1.mp4
Proffered Paper session 2 Q&A 2.mp4
Proffered Paper session 2 Safety and Efficacy of Combined Treatment with Tumor Infiltrating Lymphocytes (TILs).mp4
Proffered Paper session 2 Safety and Efficacy of Combined Treatment with Tumor Infiltrating Lymphocytes (TILs).pdf
The future of CNS tumors Learning from failures and driven by biology Checkpoint blockade and CNS tumour microenvironment.mp4
The future of CNS tumors Learning from failures and driven by biology Checkpoint blockade and CNS tumour microenvironment.pdf
The future of CNS tumors Learning from failures and driven by biology Immunology and immunotherapy of meningioma.mp4
The future of CNS tumors Learning from failures and driven by biology Immunology and immunotherapy of meningioma.pdf
The future of CNS tumors Learning from failures and driven by biology Q&A and discussion.mp4
The future of CNS tumors Learning from failures and driven by biology T cell-based immunotherapy for malignant glioma.mp4
The future of CNS tumors Learning from failures and driven by biology T cell-based immunotherapy for malignant glioma.pdf
The future of immunotherapy in thoracic oncology Immunotherapy combinations in early stage NSCLC.mp4
The future of immunotherapy in thoracic oncology Immunotherapy combinations in early stage NSCLC.pdf
The future of immunotherapy in thoracic oncology Immunotherapy plus targeted therapy combinations Promises and pitfalls.mp4
The future of immunotherapy in thoracic oncology Immunotherapy plus targeted therapy combinations Promises and pitfalls.pdf
The future of immunotherapy in thoracic oncology Next-generation biomarkers of immunotherapy in NSCLC.mp4
The future of immunotherapy in thoracic oncology Next-generation biomarkers of immunotherapy in NSCLC.pdf
The future of immunotherapy in thoracic oncology Q&A and discussion.mp4
The future of immunotherapy in thoracic oncology The microbiome and immunotherapy in NSCLC.mp4
The future of immunotherapy in thoracic oncology The microbiome and immunotherapy in NSCLC.pdf